×
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
NASDAQ:GBT

Global Blood Therapeutics Stock Forecast, Price & News

$31.79
+0.86 (+2.78%)
(As of 06/24/2022 06:55 PM ET)
Add
Compare
Today's Range
$30.00
$32.78
50-Day Range
$22.30
$35.66
52-Week Range
$21.65
$40.69
Volume
3.15 million shs
Average Volume
1.33 million shs
Market Capitalization
$2.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$58.67
30 days | 90 days | 365 days | Advanced Chart

Receive GBT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global Blood Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

GBT Stock Forecast (MarketRank)

Overall MarketRank

1.95 out of 5 stars

Medical Sector

639th out of 1,411 stocks

Pharmaceutical Preparations Industry

302nd out of 672 stocks

Analyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
Global Blood Therapeutics logo

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

GBT Stock News Headlines

Global Blood Therapeutics: Powerhouse Of The Future
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:GBT
Fax
N/A
Employees
457
Year Founded
N/A

Company Calendar

Last Earnings
5/04/2022
Today
6/26/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$58.67
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+84.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
12 Analysts

Profitability

Net Income
$-303.09 million
Net Margins
-146.82%
Pretax Margin
-146.57%

Debt

Sales & Book Value

Annual Sales
$194.75 million
Book Value
$3.05 per share

Miscellaneous

Free Float
62,038,000
Market Cap
$2.07 billion
Optionable
Optionable
Beta
1.11














Global Blood Therapeutics Frequently Asked Questions

Should I buy or sell Global Blood Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Global Blood Therapeutics in the last year. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Global Blood Therapeutics stock.
View analyst ratings for Global Blood Therapeutics
or view top-rated stocks.

What is Global Blood Therapeutics' stock price forecast for 2022?

12 equities research analysts have issued twelve-month target prices for Global Blood Therapeutics' shares. Their GBT stock forecasts range from $31.00 to $75.00. On average, they predict Global Blood Therapeutics' stock price to reach $58.67 in the next twelve months. This suggests a possible upside of 84.5% from the stock's current price.
View analysts' price targets for Global Blood Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Global Blood Therapeutics' stock performed in 2022?

Global Blood Therapeutics' stock was trading at $29.27 on January 1st, 2022. Since then, GBT shares have increased by 8.6% and is now trading at $31.79.
View the best growth stocks for 2022 here
.

When is Global Blood Therapeutics' next earnings date?

Global Blood Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Global Blood Therapeutics
.

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) released its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.26) EPS for the quarter, topping analysts' consensus estimates of ($1.29) by $0.03. The business earned $55.20 million during the quarter, compared to the consensus estimate of $56.13 million. Global Blood Therapeutics had a negative net margin of 146.82% and a negative trailing twelve-month return on equity of 129.74%. The firm's quarterly revenue was up 41.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.21) EPS.
View Global Blood Therapeutics' earnings history
.

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the following people:
  • Dr. Ted W. Love M.D., Pres, CEO & Director (Age 63, Pay $1.06M)
  • Mr. Jeffrey S. Farrow, CFO & Principal Accounting Officer (Age 60, Pay $672.67k)
  • Ms. Jung E. Choi, Chief Bus. & Strategy Officer (Age 52, Pay $645k)
  • Mr. David L. Johnson, Chief Commercial Officer (Age 53, Pay $661.5k)
  • Dr. Kim Smith-Whitley M.D., Exec. VP and Head of R&D (Age 61, Pay $654k)
  • Dr. David R. Phillips, Founder & Advisor
  • Dr. Matthew P. Jacobson Ph.D., Founder & Advisor
  • Dr. Andrej Sali Ph.D., Founder & Advisor
  • Ms. Nazila Habibizad, Exec. VP of Operations (Age 59)
  • Stephanie Yao, Sr. Director of Corp. Communications & Investor Relations

What is Ted W. Love, M.D.'s approval rating as Global Blood Therapeutics' CEO?

13 employees have rated Global Blood Therapeutics CEO Ted W. Love, M.D. on Glassdoor.com. Ted W. Love, M.D. has an approval rating of 100% among Global Blood Therapeutics' employees. This puts Ted W. Love, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Global Blood Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Global Blood Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), Advanced Micro Devices (AMD), Gilead Sciences (GILD) and Square (SQ).

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an IPO on Wednesday, August 12th 2015. The company issued 6,000,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

Who are Global Blood Therapeutics' major shareholders?

Global Blood Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Eubel Brady & Suttman Asset Management Inc. (26.61%), Vanguard Group Inc. (9.25%), BlackRock Inc. (8.12%), State Street Corp (5.31%), Deep Track Capital LP (3.54%) and Goldman Sachs Group Inc. (2.82%). Company insiders that own Global Blood Therapeutics stock include Dawn Svoronos, De Dominicis Robert, Deval L Patrick, Eric Fink, Jeffrey S Farrow, Joshua Lehrer-Graiwer, Lesley Ann Calhoun, Mark L Perry, Philip A Pizzo, Scott W Morrison, Ted W Love, Tricia Borga Suvari and Willie L Jr Brown.
View institutional ownership trends for Global Blood Therapeutics
.

Which institutional investors are selling Global Blood Therapeutics stock?

GBT stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., EULAV Asset Management, Hsbc Holdings PLC, BlackRock Inc., Ensign Peak Advisors Inc, TD Asset Management Inc., Group One Trading L.P., and Northern Trust Corp. Company insiders that have sold Global Blood Therapeutics company stock in the last two years include Eric Fink, Jeffrey S Farrow, Philip A Pizzo, and Scott W Morrison.
View insider buying and selling activity for Global Blood Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Global Blood Therapeutics stock?

GBT stock was purchased by a variety of institutional investors in the last quarter, including Eubel Brady & Suttman Asset Management Inc., Goldman Sachs Group Inc., Fairmount Funds Management LLC, Quinn Opportunity Partners LLC, Deep Track Capital LP, State Street Corp, Royal Bank of Canada, and Mizuho Markets Americas LLC.
View insider buying and selling activity for Global Blood Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Global Blood Therapeutics?

Shares of GBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Global Blood Therapeutics' stock price today?

One share of GBT stock can currently be purchased for approximately $31.79.

How much money does Global Blood Therapeutics make?

Global Blood Therapeutics (NASDAQ:GBT) has a market capitalization of $2.07 billion and generates $194.75 million in revenue each year. The company earns $-303.09 million in net income (profit) each year or ($4.87) on an earnings per share basis.

How many employees does Global Blood Therapeutics have?

Global Blood Therapeutics employs 457 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 171 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Global Blood Therapeutics is www.gbt.com. The company can be reached via phone at (650) 741-7700 or via email at [email protected].

This page (NASDAQ:GBT) was last updated on 6/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.